These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 14506743)

  • 1. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors.
    van der Burg SH; Menon AG; Redeker A; Franken KL; Drijfhout JW; Tollenaar RA; Hartgrink HH; van de Velde CJ; Kuppen PJ; Melief CJ; Offringa R
    Int J Cancer; 2003 Nov; 107(3):425-33. PubMed ID: 14506743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
    Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
    Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer.
    van der Burg SH; de Cock K; Menon AG; Franken KL; Palmen M; Redeker A; Drijfhout J; Kuppen PJ; van de Velde C; Erdile L; Tollenaar RA; Melief CJ; Offringa R
    Eur J Immunol; 2001 Jan; 31(1):146-55. PubMed ID: 11169448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
    van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
    Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
    Lambeck A; Leffers N; Hoogeboom BN; Sluiter W; Hamming I; Klip H; ten Hoor K; Esajas M; van Oven M; Drijfhout JW; Platteel I; Offringa R; Hollema H; Melief K; van der Burg S; van der Zee A; Daemen T; Nijman H
    Int J Cancer; 2007 Aug; 121(3):606-14. PubMed ID: 17415711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells.
    Zwaveling S; Vierboom MP; Ferreira Mota SC; Hendriks JA; Ooms ME; Sutmuller RP; Franken KL; Nijman HW; Ossendorp F; Van Der Burg SH; Offringa R; Melief CJ
    Cancer Res; 2002 Nov; 62(21):6187-93. PubMed ID: 12414646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen.
    Lauwen MM; Zwaveling S; de Quartel L; Ferreira Mota SC; Grashorn JA; Melief CJ; van der Burg SH; Offringa R
    Cancer Res; 2008 Feb; 68(3):893-900. PubMed ID: 18245492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.
    de Jong A; van der Burg SH; Kwappenberg KM; van der Hulst JM; Franken KL; Geluk A; van Meijgaarden KE; Drijfhout JW; Kenter G; Vermeij P; Melief CJ; Offringa R
    Cancer Res; 2002 Jan; 62(2):472-9. PubMed ID: 11809698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.
    Leffers N; Lambeck AJ; Gooden MJ; Hoogeboom BN; Wolf R; Hamming IE; Hepkema BG; Willemse PH; Molmans BH; Hollema H; Drijfhout JW; Sluiter WJ; Valentijn AR; Fathers LM; Oostendorp J; van der Zee AG; Melief CJ; van der Burg SH; Daemen T; Nijman HW
    Int J Cancer; 2009 Nov; 125(9):2104-13. PubMed ID: 19621448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma.
    Bueter M; Gasser M; Schramm N; Lebedeva T; Tocco G; Gerstlauer C; Grimm M; Nichiporuk E; Thalheimer A; Thiede A; Meyer D; Benichou G; Waaga-Gasser AM
    Int J Oncol; 2006 Feb; 28(2):431-8. PubMed ID: 16391798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of cancer through targeting of the p53 tumor antigen.
    Zwaveling S; Van der Burg SH; Menon AG; Melief CJ; Offringa R
    Arch Immunol Ther Exp (Warsz); 2002; 50(5):297-305. PubMed ID: 12455863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stat6 activity-related Th2 cytokine profile and tumor growth advantage of human colorectal cancer cells in vitro and in vivo.
    Li BH; Xu SB; Li F; Zou XG; Saimaiti A; Simayi D; Wang YH; Zhang Y; Yuan J; Zhang WJ
    Cell Signal; 2012 Mar; 24(3):718-25. PubMed ID: 22108090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of antigen-presenting cells in the polarized development of helper T cell subsets: evidence for differential cytokine production by Th0 cells in response to antigen presentation by B cells and macrophages.
    Duncan DD; Swain SL
    Eur J Immunol; 1994 Oct; 24(10):2506-14. PubMed ID: 7925578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity.
    Cecil DL; Park KH; Gad E; Childs JS; Higgins DM; Plymate SR; Disis ML
    Breast Cancer Res Treat; 2013 Jun; 139(3):657-65. PubMed ID: 23749321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of T helper epitopes from prostatic acid phosphatase.
    McNeel DG; Nguyen LD; Disis ML
    Cancer Res; 2001 Jul; 61(13):5161-7. PubMed ID: 11431355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different patterns of cytokine induction in cultures of respiratory syncytial (RS) virus-specific human TH cell lines following stimulation with RS virus and RS virus proteins.
    Jackson M; Scott R
    J Med Virol; 1996 Jul; 49(3):161-9. PubMed ID: 8818960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.
    Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH
    Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of helper T cells in the humoral immune responses against 53-kDa outer membrane protein from Porphyromonas gingivalis.
    Kato N; Ohyama H; Nishimura F; Matsushita S; Takashiba S; Murayama Y
    Oral Microbiol Immunol; 2005 Apr; 20(2):112-7. PubMed ID: 15720572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of helper/inducer T lymphocytes. IV. Stimulation of resting and activated B cells by Th1 and Th2 clones.
    Abbas AK; Urioste S; Collins TL; Boom WH
    J Immunol; 1990 Mar; 144(6):2031-7. PubMed ID: 2138191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.